# Antibody-mediated Rejection FDA approvals and PDUFA dates

Canonical: https://sec-api.dev/indications/antibody-mediated-rejection

> 4 upcoming FDA catalysts in antibody-mediated Rejection: felzartamab (BIIB) on December 2026 (primary completion); felzartamab (BIIB) on Dec 2026 to Mar 2027 (topline data readout); efgartigimod ph20 sc - prefilled syringe (ARGX) on November 2027 (primary completion); efgartigimod ph20 sc - prefilled syringe (ARGX) on Nov 2027 to Feb 2028 (topline data readout).

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: month only, quarter only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| December 2026 | [Felzartamab primary completion](https://sec-api.dev/pdufa/felzartamab) | BIIB | Antibody-mediated Rejection | scheduled | "NCT06685757 (A Study to Learn More About the Effects and Safety of Felzartamab Infusions in Adults With Kidney Transplants Who Have Antibody-Mediated Rejection (AMR)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-12-01 (ESTIMATED); Lead Sponsor Biogen." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06685757)) |
| Dec 2026 to Mar 2027 | [Felzartamab topline data readout](https://sec-api.dev/pdufa/felzartamab) | BIIB | Antibody-mediated Rejection | scheduled | "NCT06685757 (A Study to Learn More About the Effects and Safety of Felzartamab Infusions in Adults With Kidney Transplants Who Have Antibody-Mediated Rejection (AMR)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-12-01 (ESTIMATED); Lead Sponsor Biogen." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06685757)) |
| November 2027 | [Efgartigimod ph20 sc - prefilled syringe primary completion](https://sec-api.dev/pdufa/efgartigimod-ph20-sc-prefilled-syringe) | ARGX | Antibody-mediated Rejection | scheduled | "NCT06503731 (A Study to Evaluate the Safety and Tolerability of Efgartigimod PH20 SC Given by Prefilled Syringe in Kidney Transplant Recipients With Antibody-Mediated Rejection (AMR)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2027-11 (ESTIMATED); Lead Sponsor argenx." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06503731)) |
| Nov 2027 to Feb 2028 | [Efgartigimod ph20 sc - prefilled syringe topline data readout](https://sec-api.dev/pdufa/efgartigimod-ph20-sc-prefilled-syringe) | ARGX | Antibody-mediated Rejection | scheduled | "NCT06503731 (A Study to Evaluate the Safety and Tolerability of Efgartigimod PH20 SC Given by Prefilled Syringe in Kidney Transplant Recipients With Antibody-Mediated Rejection (AMR)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2027-11 (ESTIMATED); Lead Sponsor argenx." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06503731)) |

## Drugs

- [Felzartamab](https://sec-api.dev/pdufa/felzartamab) (BIIB)
- [Efgartigimod ph20 sc - prefilled syringe](https://sec-api.dev/pdufa/efgartigimod-ph20-sc-prefilled-syringe) (ARGX)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/indications/antibody-mediated-rejection.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Antibody-mediated Rejection FDA approvals and PDUFA dates." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/indications/antibody-mediated-rejection

```bibtex
@misc{secapidev_indications_antibody_mediated_rejection_20261116,
  title        = {Antibody-mediated Rejection FDA approvals and PDUFA dates},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/indications/antibody-mediated-rejection}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_indications_antibody_mediated_rejection_20261116","title":"Antibody-mediated Rejection FDA approvals and PDUFA dates","publisher":"sec-api.dev","URL":"https://sec-api.dev/indications/antibody-mediated-rejection","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
